Efficacy and Safety of Dalbavancin As Suppressive Therapy

Launched by HOSPICES CIVILS DE LYON · Mar 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called Dalbavancin (DAL) for treating acute or chronic infections. DAL is a type of antibiotic that works by killing bacteria, specifically targeting certain harmful types of bacteria known as Gram-positive bacteria, like Staphylococcus and Streptococcus. The trial is looking for adult participants (18 years and older) who have received DAL treatment for infections that have not improved with other treatments.

If you or a loved one decides to participate, you will be part of a study that aims to find out how well DAL works and whether it is safe to use. The trial is currently recruiting participants, and those who join will be closely monitored to track their health and any effects from the medication. It's important to know that participants must have previously received DAL for their infections and must not be younger than 18. This trial hopes to gather valuable information that could help improve treatment options for future patients with similar infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • \> 18 years
• • Patients received SAT with DAL for acute or chronic infections (defined as a long-standing infection due to a previously uneradicated pathogen, following unsuccessful antibiotic or surgical treatments) between July 2019 and December 2024
• • Patient who was informed and did not object to participating in the study
• Exclusion Criteria:
• • -\< 18 years
• • Subjects who received DAL not for SAT purposes